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Introduction {#sec1}
============

The evolutionarily conserved mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) is a master regulator of cell growth and metabolism ([@bib9], [@bib11]), and comprises mTOR, regulatory-associated protein of mammalian target of rapamycin (Raptor), mTOR-associated protein, LST8 homolog, proline-rich Akt substrate of 40 kDa, and DEP domain-containing mTOR-interacting protein ([@bib11]). Dysregulation of mTORC1 is common in human diseases, including cancer, diabetes, and neurodegenerative diseases, such as Alzheimer\'s disease and Parkinson\'s disease ([@bib11], [@bib22], [@bib26]). In mammals, growth factors and intracellular energy signals stimulate mTORC1 activity through inhibition of the tuberous sclerosis complex (TSC) 1 and 2, a negative regulator of mTORC1 ([@bib4]). Amino acids (AAs) signal to mTORC1 through Rag GTPases independently of the TSC complex ([@bib9], [@bib20]). Previous reports showed that Rag heterodimers interact with mTORC1 and that AAs induce the mTORC1-Rag interaction by promoting the loading of RagB with GTP, enabling it to directly interact with Raptor ([@bib20]). Activation of the mTORC1 pathway by AAs correlates with the translocation of mTORC1 from undefined locations to lysosomes where it encounters RHEB, a potent mTORC1 activator ([@bib5], [@bib20]). The Ragulator complex, which is encoded by the *MAPKSP1*, *ROBLD3*, and *c11orf59* genes ([@bib19]), interacts with the Rag GTPases, recruits them to lysosomes, and is essential for mTORC1 activation ([@bib19]).

Among AAs, leucine (Leu) has been implicated in mTORC1 activation ([@bib7], [@bib20]) and many have searched for the Leu sensor(s) in cells that control mTORC1 activity ([@bib6], [@bib12], [@bib21], [@bib24], [@bib25]). Recently, Sestrin2, a GATOR2-interacting protein that inhibits mTORC1 ([@bib2], [@bib16], [@bib21]), was reported as an intracellular Leu sensor for mTORC1 pathway in HEK293T cells ([@bib24]). Other proposed Leu sensors include leucyl-tRNA synthetase (LARS) ([@bib6], [@bib8]) and glutamate dehydrogenase (GLUD1) ([@bib12]). Here, by studying enzymes regulating the metabolism of Leu to acetyl-coenzyme A (AcCoA), we have discovered that Leu signaling to mTORC1 does not necessarily require a "sensor" in some cell lines and primary cells, as AcCoA positively regulates mTORC1 via Raptor acetylation.

Results and Discussion {#sec2}
======================

MCCC1, Which Regulates Leu Metabolism, Impacts mTORC1 Signaling in HeLa Cells {#sec2.1}
-----------------------------------------------------------------------------

To determine whether Leu catabolism can regulate mTORC1 in HeLa cells, we knocked down MCCC1, a key enzyme in the Leu metabolic pathway ([Figure 1](#fig1){ref-type="fig"}A) ([@bib3]), which decreased levels of markers of mTORC1 activity: phosphorylated S6K1, 4E-BP1 (mTORC1 kinase substrates), and S6 (S6K1 substrate) ([Figure 1](#fig1){ref-type="fig"}B). When *MCCC1* cDNA was transfected into MCCC1 knockdown cells, it rescued mTORC1 activity ([Figure 1](#fig1){ref-type="fig"}C). These data suggested that MCCC1 could regulate mTORC1. MCCC1 knockdown did not obviously perturb mitochondrial morphology or cause any reactive oxygen species (ROS) elevation, and N-acetylcysteine, an ROS scavenger, did not rescue mTORC1 inhibition in MCCC1 knockdown cells ([Figures S1](#mmc1){ref-type="supplementary-material"}A--S1C). Since treatment with Leu stimulates lysosomal recruitment and activation of mTORC1 under AA starvation conditions, we determined whether MCCC1 similarly affected the lysosomal translocation of mTORC1. When we added Leu to AA-starved cells, mTORC1 appeared in puncta-like structures that co-localized with LAMP1-positive vesicles (late endosomes/lysosomes) in control cells ([Figure 1](#fig1){ref-type="fig"}D, left panel), but the mTORC1 redistribution onto lysosomes was reduced upon knockdown of MCCC1 ([Figure 1](#fig1){ref-type="fig"}D, right panel). Similarly, under AA starvation conditions, neither Leu nor its direct metabolite alpha-ketoisocaproate, which is upstream of MCCC1 ([Figure 1](#fig1){ref-type="fig"}A), rescued the mTORC1 pathway in MCCC1 knockdown cells ([Figures 1](#fig1){ref-type="fig"}D and 1E). However, 3-hydroxy-3-methylglutaryl-coenzyme A and 1 μM AcCoA ([Figure S1](#mmc1){ref-type="supplementary-material"}D shows that this results in physiologically relevant levels intracellularly), Leu metabolites downstream of MCCC1 ([Figure 1](#fig1){ref-type="fig"}A), could restore mTORC1 activity in MCCC1 knockdown cells ([Figure 1](#fig1){ref-type="fig"}F), indicating that Leu catabolism is essential for mTORC1 regulation. As we observed with MCCC1 knockdown, depletion of AUH (the enzyme immediately downstream of MCCC1 in the pathway from Leu to AcCoA; [Figure 1](#fig1){ref-type="fig"}A) decreased mTORC1 activity, and Leu treatment failed to rescue mTORC1 activity in AA-starved, AUH knockdown cells ([Figures S1](#mmc1){ref-type="supplementary-material"}E--S1G). To determine whether other branched chain AAs can also regulate mTORC1, we treated starved cells with isoleucine (Ile) and valine (Val). Val had no effect, and only high concentrations of Ile could rescue mTORC1 activity in AA-starved cells ([Figure S1](#mmc1){ref-type="supplementary-material"}H).Figure 1MCCC1, Which Regulates Leu Metabolism, Modifies mTORC1 Signaling in HeLa Cells(A) Leu metabolic pathway. Blue box shows MCCC1 protein.(B) Control and MCCC1 knockdown (transfected with pool or four deconvoluted oligos) HeLa cells were used to determine whether MCCC1 can regulate mTORC1 signal. Blots are representative of at least three independent experiments (N = 3). P- indicates phosphorylated protein. Note that oligo no. 2 has not knocked down MCCC1. p-S6K1 (Thr389), p-S6 (Ser235/236), p-4E-BP1 (Thr37/46).(C) Re-introduction to MCCC1 knockdown HeLa cells with MCCC1 cDNA. Blots are representative of at least three independent experiments (N = 3).(D) Control and MCCC1 knockdown HeLa cells were either left untreated, AA starved for 2 hr, or AA starved and then Leu was added for 0.5 hr, then immunostained with mTOR and LAMP1 antibodies as shown. Co-localization panels show an overlap between mTOR and LAMP1 signals. The fraction of mTOR-positive lysosomes were determined using Volocity software. Values are mean ± SEM. n = ∼50 cells. ^∗^p \< 0.05, ^∗∗^p \< 0.01 versus control cells; ^\#\#^p \< 0.01 versus AA-starved cells (two-tailed t test); ns, not significant. Scale bars, 5 μm and 1 μm (enlarged images). The experiment was repeated an additional two times (N = 3). NC, normal control.(E) Immunoblots of control and MCCC1-knockdown HeLa cells with or without Leu or alpha-ketoisocaproate (KIC) under AA-starved conditions. Blots are representative of at least three independent experiments (N = 3). ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 versus control cells; ^\#^p \< 0.05, ^\#\#^p \< 0.01 versus AA-starved cells; ^&&^p \< 0.01 versus MCCC1 knockdown cells. p-ULK1 (Ser757).(F) Immunoblots of control and MCCC1-knockdown HeLa cells with or without 3-hydroxy-3-methylglutaryl-coenzyme A (HCoA) or AcCoA. ^∗^p \< 0.05, ^∗∗^p \< 0.01 versus control cells; ^\#^p \< 0.05, ^\#\#^p \< 0.01 versus AA-starved cells. N = 3.

AcCoA, the Final Leu Metabolite, Regulates mTORC1 under AA-Starved Conditions in Some Cell Types {#sec2.2}
------------------------------------------------------------------------------------------------

Total and cytosolic AcCoA levels were decreased in both MCCC1 knockdown HeLa cells and AA-starved HeLa cells ([Figures 2](#fig2){ref-type="fig"}A and 2B). Leu and dichloroacetate (DCA, which enhances AcCoA levels by activating pyruvate dehydrogenase to produce AcCoA from pyruvate rather than Leu; [@bib15]) rescued the reduction of AcCoA under AA starvation conditions ([Figure 2](#fig2){ref-type="fig"}B). Leu metabolites, including AcCoA and DCA, rescued mTORC1 inhibition by AA starvation ([Figures S1](#mmc1){ref-type="supplementary-material"}H and [2](#fig2){ref-type="fig"}C--2E). To determine whether cytosolic AcCoA levels are important for this mTORC1 rescue in AA-starved HeLa cells, we knocked down ATP citrate lyase (ACLY), which makes a major contribution to cytosolic AcCoA production in many cell types ([@bib15]). In ACLY knockdown HeLa cells, total and cytosolic AcCoA levels were decreased ([Figure 2](#fig2){ref-type="fig"}F), and the increase of mTORC1 activity mediated by Leu or DCA in-starved cells was blunted ([Figure 2](#fig2){ref-type="fig"}G). Next, as we observed in HeLa cells, Leu and DCA rescued the inhibition of mTORC1 resulting from AA starvation in human neuroblastoma SH-SY5Y cells ([Figure 2](#fig2){ref-type="fig"}H). Likewise DCA could rescue mTORC1 activity in Mccc1 knockdown primary neurons ([Figure 2](#fig2){ref-type="fig"}I). Furthermore, we found that Leu metabolites rescued mTORC1 inhibition resulting from AA starvation in primary neurons, as we observed in SH-SY5Y or in HeLa cells ([Figure 2](#fig2){ref-type="fig"}J), which we confirmed by immunostaining with an anti-phosphorylated S6 antibody ([Figure 2](#fig2){ref-type="fig"}K). Consistent with these data, mTORC1 redistribution onto lysosomes in primary neurons was reduced under AA starvation conditions, and this was rescued by the addition of Leu or DCA ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). Interestingly, unlike HeLa and neuronal cells, HEK293T cells showed different patterns of mTORC1 regulation ([Figures S2](#mmc1){ref-type="supplementary-material"}C--S2E), which did not appear to be obviously dependent on Leu metabolism. We found that DCA could reverse mTORC1 inhibition by AA starvation in epithelial cell lines (MCF7 and MCF10A), a glial cell line (H4), and mesenchymal stem cells, but not in primary mouse embryonic fibroblasts (MEFs) and HEK293T cells ([Figure S2](#mmc1){ref-type="supplementary-material"}F). We analyzed AcCoA levels in cell lines where mTORC1 signaling after starvation was sensitive/insensitive to DCA/AcCoA. Our data suggest that non-responsiveness may occur either when cells have very high AcCoA levels in nutrient replete media, or if they fail to lower AcCoA levels after AA starvation ([Figure S2](#mmc1){ref-type="supplementary-material"}G).Figure 2AcCoA, the Metabolite of Leu Metabolism, Is Important for mTORC1 Regulation in Some Cell Types(A) Measurement of total and cytosolic AcCoA levels in control and MCCC1 knockdown HeLa cells. ^∗∗^p \< 0.01 versus control cells. N = 3.(B) Measurement of total and cytosolic AcCoA levels on HeLa cells with or without Leu or DCA under AA-starved conditions. ^∗∗^p \< 0.01 versus control cells; ^\#^p \< 0.05, ^\#\#^p \< 0.01 versus AA-starved cells. N = 4.(C) mTORC1 regulation under AA-starved conditions with or without Leu, KIC, HCoA, or DCA in HeLa cells. Blots are representative of at least three independent experiments (N = 3).(D) mTORC1 distribution to lysosomal membranes under AA starvation with or without Leu, KIC, DCA, or AcCoA in HeLa cells. Scale bars, 5 μm and 1 μm (enlarged images).(E) Quantification of (D). Values are mean ± SEM. n = about 60 cells. ^∗∗^p \< 0.01 versus control cells; ^\#\#^p \< 0.01, ^\#\#\#^p \< 0.001 versus AA-starved cells (two-tailed t test).(F) Measurement of total and cytosolic AcCoA levels in control and ACLY knockdown HeLa cells. ^∗∗^p \< 0.01 versus control cells. N = 3.(G) Immunoblots of control and ACLY knockdown HeLa cells with or without Leu or DCA under AA-starved conditions. Blots are representative of at least three independent experiments. N = 3.(H) mTORC1 regulation under AA-starved conditions with or without Leu or DCA in SH-SY5Y cells. ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 versus control cells; ^\#^p \< 0.05, ^\#\#^p \< 0.01 versus AA-starved cells (two-tailed t test). NC, normal control; NEA, non-essential AA mixture; EA, essential AA mixture. N = 4.(I) The role of DCA in Mccc1 knockdown primary neurons. ^∗∗^p \< 0.01 versus control small hairpin RNA (shRNA)-infected neurons; ^\#^p \< 0.05 versus Mccc1 shRNA-infected neurons. N = 3.(J) mTORC1 regulation under starved condition with or without Leu, KIC, HCoA, or DCA on primary neurons. ^∗^p \< 0.01, ^∗∗^p \< 0.01 versus control neurons; ^\#^p \< 0.05 versus starved neurons. N = 3.(K) mTORC1 regulation using phosphorylated S6 (p-S6; Ser235/236) antibody in primary neurons. Values are mean ± SEM. n = about 50 cells. ^∗∗^p \< 0.01 versus control neurons; ^\#^p \< 0.05 versus starved neurons (two-tailed t test). Scale bar, 10 μm.

Next, we investigated the mechanism by which Leu metabolites regulate mTORC1. Since Rag GTPase recruits mTORC1 to lysosomes ([@bib9]) and AA starvation with/without Leu metabolites regulates mTORC1 lysosomal localization ([Figures 1](#fig1){ref-type="fig"}D and [2](#fig2){ref-type="fig"}D), we assessed if the Ragulator complex on lysosomes influenced mTORC1 regulation by AcCoA. RagA and RagB double knockdown or knockdown of LAMTOR1 (which anchors the Ragulator complex to lysosomes) abrogated the ability of AcCoA to rescue mTORC1 inhibition in AA-starved HeLa cells ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Addition of Leu or AcCoA to starved cells did not alter the localization of the Rag complex on lysosomes ([Figure S3](#mmc1){ref-type="supplementary-material"}B), indicating that Leu metabolites can regulate mTORC1 in a Rag complex-dependent manner without altering the localization of Rag complex. To determine whether known Leu sensors are required for mTORC1 activity rescue by AcCoA in AA-starved HeLa cells, we knocked down Sestrin (Sestrin 1, 2), LARS, and GLUD1, and found that mTORC1 activity was restored by DCA and partially by Leu ([Figures S3](#mmc1){ref-type="supplementary-material"}C and S3D) in all cases. While we cannot exclude that complete knockout of these sensors would not have an effect, our data suggested that partial loss of these sensors is not limiting for the pathway we have described in HeLa cells, although the slightly blunted response to Leu in the Leu sensor knockdown cells may reflect roles for these pathways in addition to AcCoA biogenesis from Leu in regulating mTORC1 activity after starvation.

mTORC1 Regulation by AcCoA Is Associated with EP300 Acetyltransferase {#sec2.3}
---------------------------------------------------------------------

To determine the exact mechanism by which AcCoA regulates mTORC1 signal pathway under AA starvation conditions, we checked acetylation levels in HeLa cells because AcCoA can activate lysine (K) acetyltransferases (KATs) ([@bib15], [@bib17]). We found that starvation decreased acetylation levels globally, and the treatment with Leu and AcCoA rescued it ([Figure S3](#mmc1){ref-type="supplementary-material"}E). We found that the acetylation in the cytoplasm particularly was reduced significantly, and MCCC1 knockdown mimicked starvation conditions ([Figure S3](#mmc1){ref-type="supplementary-material"}F). Next, we investigated how alteration in acetylation levels by AcCoA could regulate mTORC1. Because EP300 acetyltransferase has been reported to regulate mTORC1 signaling by AcCoA ([@bib15]), we treated cells with the specific EP300 inhibitors c646 and spermidine ([@bib18]). We found that these compounds or EP300 knockdown blocked the ability of AcCoA to rescue mTORC1 activity in AA-starved HeLa cells ([Figures 3](#fig3){ref-type="fig"}A and 3B). However, knockdown of other common acetyltransferases, KAT2A and KAT2B, did not block the effect of AcCoA on mTORC1 activity under AA starvation ([Figure 3](#fig3){ref-type="fig"}C). Consistent with these data, the EP300 activator CTB, a simplified analog of CTPB, rescued mTORC1 inhibition by AA starvation ([Figure S3](#mmc1){ref-type="supplementary-material"}G). To determine whether the acetyltransferase activity of EP300 is important for mTORC1 regulation, we used an EP300 acetyltransferase activity-dead mutant (EP300 Mut), and found that EP300 Mut failed to rescue mTORC1 signal by AcCoA in EP300 knockdown cells, while rescue was seen with the wild-type (EP300 WT) protein ([Figure 3](#fig3){ref-type="fig"}B). Likewise, immunostaining showed that EP300 knockdown prevented the lysosomal relocalization of mTORC1 in response to AcCoA ([Figure 3](#fig3){ref-type="fig"}D). EP300 did not appear to regulate mTORC2 activity (assessed by phosphorylation of PKCα/β or AKT) ([Figure 3](#fig3){ref-type="fig"}E).Figure 3mTORC1 Is Regulated by AcCoA via EP300 Acetyltransferase(A) EP300 inhibitors (c646 and spermidine \[Sp\]) inhibit AcCoA-induced rescue of mTORC1 activity in AA-starved HeLa cells. N = 4.(B) Effects of EP300 knockdown with replacement with wild-type (EP300 WT) or catalytically inactive EP300 (EP300 Mut) on mTORC1 signaling in response to AA deprivation with or without AcCoA. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 versus control cells; ^\#^p \< 0.05, ^\#\#^p \< 0.01, ^\#\#\#^p \< 0.001 versus AA-starved cells; ^&^p \< 0.05 versus EP300 knockdown cells (two-tailed t test); ns, not significant. N = 3.(C) mTORC1 regulation by AcCoA in control HeLa cells or in EP300, KAT2A, or KAT2B knockdown HeLa cells. Blots are representative of at least three independent experiments (N = 3).(D) mTORC1 distribution onto lysosomal membranes on control and EP300 knockdown HeLa cells in response to AA deprivation with or without AcCoA. Values are mean ± SEM. n = about 50 cells. ^∗^p \< 0.05 versus control cells; ^\#^p \< 0.05 versus AA-starved cells (two-tailed t test). Scale bars, 5 μm and 1 μm (enlarged images).(E) mTORC2 regulation by EP300 activity. ^∗^p \< 0.05 versus control cells; ^\#^p \< 0.05 versus AA-starved cells (two-tailed t test). N = 3. p-PKCα/β (Thr638/641), p-AKT (Ser473).(F) Localization of EP300 to the nucleus under AA-starved conditions. N, nuclear; C, cytoplasm. n = about 30 cells. ^∗^p \< 0.05, ^∗∗^p \< 0.01 versus control cells. Scale bar, 5 μm.(G) Nuclear or cytoplasmic EP300 activities under AA-starved condition. ^∗^p \< 0.05 versus control cells. N = 4.(H) Change in EP300 localization under AA starvation with or without Leu or AcCoA. ^∗∗^p \< 0.01 versus control cells; ^\#^p \< 0.05, ^\#\#^p \< 0.01, ^\#\#\#^p \< 0.001 versus AA-starved cells (two-tailed t test). N = 3.(I) Differential regulation of acetylation of nuclear (H3) and cytoplasmic (ATG7 and Raptor) substrates by EP300 under basal and AA starvation conditions. N = 3.

To investigate how starvation regulates EP300 activity, we measured EP300 activity directly in total lysates and found that starvation for 2 hr did not alter total EP300 activity ([Figure S3](#mmc1){ref-type="supplementary-material"}H). Consistent with previous reports showing that starvation altered EP300 localization ([@bib23]), we found that EP300 was located both in the nucleus and cytoplasm in basal conditions, and that AA starvation caused it to relocalize predominantly into the nucleus ([Figure 3](#fig3){ref-type="fig"}F). Likewise, AA starvation decreased the activity of cytoplasmic EP300 ([Figure 3](#fig3){ref-type="fig"}G). The addition of Leu and AcCoA to AA-starved cells caused a partial redistribution of EP300 into the cytoplasm from the nucleus ([Figure 3](#fig3){ref-type="fig"}H). Consistent with these data, AA starvation increased the acetylation of histone H3, a nuclear EP300 substrate, while acetylation of a cytoplasmic EP300 substrate, ATG7, was decreased ([Figure 3](#fig3){ref-type="fig"}I). These data indicate that mTORC1 regulation by AcCoA under AA starvation conditions is associated with changes in cytoplasmic EP300 acetyltransferase activity.

Raptor Acetylation by EP300 Is Important for mTORC1 Regulation {#sec2.4}
--------------------------------------------------------------

Having established that EP300 is able to modulate mTORC1 activity and its translocation to the lysosomes ([Figure 3](#fig3){ref-type="fig"}), we next investigated the mechanism for this effect. EP300 small interfering RNA or chemical inhibition did not alter the localization of Rag complex on the lysosome ([Figure S3](#mmc1){ref-type="supplementary-material"}I), suggesting that EP300 acted upstream of this complex and that it may interact directly with mTORC1. We therefore assessed which component of mTORC1 bound EP300, and found that only Raptor interacted with it ([Figures 4](#fig4){ref-type="fig"}A, [S4](#mmc1){ref-type="supplementary-material"}A, and S4B) independently of EP300 activity ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Furthermore, we were able to demonstrate that Raptor is acetylated, and that this acetylation was reduced by AA depletion ([Figures 3](#fig3){ref-type="fig"}I and [4](#fig4){ref-type="fig"}B) or EP300 inhibition with c646 ([Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D), while the EP300 activator CTB increased Raptor acetylation ([Figure S4](#mmc1){ref-type="supplementary-material"}E). Consistent with [Figure 3](#fig3){ref-type="fig"}C, neither KAT2A nor KAT2B induced Raptor acetylation ([Figure 4](#fig4){ref-type="fig"}C). We next determined which site in Raptor could be acetylated to regulate mTORC1. A previous study showed that K840 in Raptor can be acetylated and can regulate mTORC1 under specific conditions ([@bib14]). However, the Raptor K840R mutant did not alter mTORC1 activity in AA-starved cells with/without AcCoA ([Figure S4](#mmc1){ref-type="supplementary-material"}F) and, unexpectedly, mutation of K840 in Raptor did not prevent its acetylation in HeLa cells ([Figure S4](#mmc1){ref-type="supplementary-material"}G). Recent liquid chromatography-mass spectrometry data showed that K1097 in Raptor can be acetylated ([@bib13]). We found that Raptor K1097R (KR) mutant had reduced acetylation ([Figure 4](#fig4){ref-type="fig"}D) and cells where Raptor was knocked down and replaced with Raptor KR failed to restore the mTORC1 activity in AA starvation with AcCoA ([Figure 4](#fig4){ref-type="fig"}E). Raptor KR did not alter the formation of mTORC1 ([Figure S4](#mmc1){ref-type="supplementary-material"}H), but bound less to the Rag complex ([Figures 4](#fig4){ref-type="fig"}F and 4G). Likewise, immunostaining showed that cells with Raptor KR had decreased mTORC1 on lysosomal membranes ([Figure 4](#fig4){ref-type="fig"}H).Figure 4Raptor Acetylation by EP300 Is Important for mTORC1 Regulation(A) Interaction of EP300 with components of the mTORC1 using GFP-trap or immunoprecipitation (IP) with EP300 antibody. GFP- or YFP-tagged mTORC1 constructs (GFP vector, YFP-mTOR, YFP-Raptor, YFP-proline-rich Akt substrate of 40 kDa \[PRAS40\], and YFP-DEP domain-containing mTOR-interacting protein \[DEPTOR\]) were used. Asterisks indicate the predicted position of mTOR, PRAS40, or DEPTOR. HC, heavy immunoglobulin G (IgG) chain; LC, light IgG chain. N = 3.(B) Decreased acetylation of Raptor under AA-starved conditions independently of interaction with mTOR. Acetylated mTOR level was not altered by AA starvation. ^∗∗^p \< 0.01 versus control cells. N = 3.(C) Acetylation of Raptor by EP300, not by KAT2A or KAT2B. ^∗∗∗^p \< 0.001 versus control cells. N = 3.(D) Raptor K1097R mutant (KR) is not acetylated. WT, wild-type; KR, K1097R mutant. ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 versus Raptor WT-expressing control cells. N = 3.(E) Cells were depleted of Raptor with small interfering RNA (siRNA) and reconstituted with Raptor WT or KR, then analyzed for mTORC1 activity in the presence or absence of AA, the latter with/without AcCoA in HeLa cells. ^∗^p \< 0.05, ^∗∗^p \< 0.01 versus Raptor WT-expressing control cells; ^\#^p \< 0.05 versus AA-starved cells; ^&^p \< 0.05 versus Raptor KR-expressing cells (two-tailed t test); ns, not significant. N = 3.(F and G) Reduced interaction of Raptor KR mutant with the Rag complex using GFP-trap (F) or IP with Flag antibody (G). N = 3.(H) mTORC1 distribution onto lysosomal membranes in HeLa cells depleted of Raptor then reconstituted with Raptor WT or Raptor KR. Scale bars, 10 μm and 2 μm (enlarged images). n = about 40 cells. ^∗∗^p \< 0.01 versus Raptor WT-expressing control cells.(I and J) Decreased AcCoA levels and acetylation of Raptor in fasted mice brains, livers, and muscles. After 22.5 hr starvation, mice were given free access to food for 1.5 hr followed by a second round of starvation for another 22.5 hr. The tissue samples from fed (n = 5) and fasted mice (n = 6) were analyzed for AcCoA (I) and acetylated Raptor (J) levels. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 versus fed mice.

AcCoA Levels and Acetylation of Raptor Are Decreased in Tissues of Fasted Mice {#sec2.5}
------------------------------------------------------------------------------

Finally, to confirm the relevance of this mTOR signaling pathway *in vivo*, we assessed it in the brains of fasted mice. As seen for AA starvation in primary neurons ([Figures 2](#fig2){ref-type="fig"}J, 2K, and [S2](#mmc1){ref-type="supplementary-material"}A), brains of fasted mice showed reduced mTORC1 activity ([Figure S4](#mmc1){ref-type="supplementary-material"}I). We were able to confirm that the levels of AcCoA, the levels of acetylated Raptor and ATG7, and EP300 activity were also decreased in mouse brains following fasting ([Figures 4](#fig4){ref-type="fig"}I, 4J, and [S4](#mmc1){ref-type="supplementary-material"}J--S4M). In addition to brain tissue, fasted mouse liver and muscle both showed significantly decreased levels of acetylated Raptor and significantly reduced AcCoA in the muscle with a non-significant trend in liver ([Figures 4](#fig4){ref-type="fig"}I and 4J).

In conclusion, while previous studies have suggested that cells require Leu sensing mechanisms to transduce nutrient status to the machinery controlling mTORC1 activity ([@bib25]), our study finds that Leu can signal directly via its metabolite AcCoA in some cell types. Increased AcCoA levels, which are found when Leu is added to AA-starved cells, activate the acetylation of Raptor at K1097. This increases its interaction with the Rag complex compared with unacetylated Raptor KR, and thus enables mTORC1 activation ([Figure S4](#mmc1){ref-type="supplementary-material"}N). Interestingly, this mechanism appears to be relevant in a variety of cell types, including neurons. However, it is not obvious in MEF cells and HEK293T cells, which have been used prominently in this field for identifying alternate Leu signaling pathways ([@bib6], [@bib24]). This raises the possibility of cell-type-specific modes of regulation of mTORC1.

Limitations of Study {#sec2.6}
--------------------

While we observed that starvation of mice decreased levels of AcCoA and Raptor acetylation in some tissues including the brain, further work is required to determine which tissues respond in this way to nutrient deprivation *in vivo*, and if these responses are different in cancers. It will be important to assess the importance of this Leu-AcCoA-mTORC1 signaling pathway in different tissues *in vivo*, in relation to other Leu-sensing mechanisms. It would be interesting to test the speculation that these different pathways whereby Leu regulates mTORC1 may act with different kinetics in different tissues after starvation is initiated *in vivo*.

STAR★Methods {#sec3}
============

Key Resources Table {#sec3.1}
-------------------
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Contact for Reagent and Resource Sharing {#sec3.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, David C. Rubinsztein (<dcr1000@cam.ac.uk>).

Experimental Model and Subject Details {#sec3.3}
--------------------------------------

### Cell Lines {#sec3.3.1}

Human cervical epithelium HeLa, human neuroblastoma cell line SH-SY5Y, human embryonic kidney cell line HEK-293T, human breast cancer cell line MCF7 and human neuroglioma cell line H4 cells (from ATCC) cultured in Dulbecco's modified Eagle's medium (DMEM) (4.5 mg l^-1^ of glucose; \#D6546)) supplemented with 10% FBS (\#F7524), 2mM L-glutamine (\#G7513) and 100Uml^-1^ penicillin and 100 mgml^-1^ streptomycin (\#P0781). Non-transformed mammary epithelial MCF10A cells were purchased from Horizon (Catalogue No. HD PAR-058) and cultured in DMEM-F12 supplemented with 5% horse serum (\#H1270), 20 ngml^-1^ hEGF (\#E9644), 0.5 μgml^-1^ hydrocortisone (\#H0135), 100 ngml^-1^ cholera toxin (\#C8052), 10 μgml^-1^ insulin (\#I9278) and 100 Uml^-1^ penicillin and 100 mgml^-1^ streptomycin (all the components were obtained from Sigma Aldrich). A human adipose-derived Mesenchymal Stem Cells (MSC) cell line was purchased from ATCC (\#PCS-500-011), and maintained in Mesenchymal Stem Cell Basal Medium (ATCC, \#PCS-500-030), supplemented using the Mesenchymal Stem Cell Growth Kit (ATCC, \#PCS-500-040), according to the manufacturer's recommendation. All the cell lines were maintained at 37°C and 5% CO~2~ and were regularly tested for mycoplasma contamination. HeLa, SHSY5Y, HEK-293T, MCF7 and MCF10A cells are female, and H4 cells are male. For starvation experiments with cell lines, cells were washed three times in Hank's balanced salt solution (Invitrogen) and incubated for 2 h at 37°C in Earle's balanced salt solution (Starvation media) (Sigma-Aldrich). All experiments with amino acid starvation and stimulation contained 10% dialyzed FBS (\#26400-036 from Invitrogen) unless otherwise indicated. The cells were stimulated with essential amino acid (AAs) at a concentration 2X of what is typically found in normal Invitrogen high-glucose DMEM.

### Primary Mouse Cortical Neurons and Primary Embryonic Fibroblasts (MEFs) {#sec3.3.2}

Primary cortical neurons were isolated from C57BL/6 mice (Jackson Laboratories) embryos at E16.5 as described previously ([@bib10]). Briefly, brains were harvested and placed in HBSS where the meninges were removed and the cerebral cortices were dissected. After incubation in Hank's Balanced Salt Solution (HBSS) with 0.25% trypsin (Gibco) for 20 min at 37°C, dissociated neurons were resuspended in HBSS and seeded on poly-D-lysine-coated 6- or 12-multiwell plates. Cells were cultured in maintenance media (Neurobasal-A medium (\#12349015, Thermo Fisher Scientific) supplemented with 2 mM GlutaMAX, 200 mM B27 supplement and 1% Penicillin--Streptomycin) at 37°C in a humidified incubator with 5% CO~2~. One half of the culture medium was changed every 2 days until treatment/infection. After 5 days of *in vitro* culturing, differentiated neurons were infected with lentiviral particles for knockdown experiments. Primary mouse embryonic fibroblasts (MEFs) were isolated from wild-type C57BL/6 mice embryos at E12, using a protocol modified from that described previously (<http://www.thermofisher.com/>). The sexes of mouse-derived primary cells were not determined, as this was not considered to impact the basic cell biology we are describing. All mouse experiments were performed with personal and project licences granted by the UK Home Office and with the approval of the University of Cambridge committee for animal studies.

### Animals {#sec3.3.3}

For all studies, 6 to 7-weeks-old C57BL/6 male or female mice were used, and all studies were performed under the jurisdiction of appropriate Home Office Project and Personal animal licences and with local Ethics Committee approval from the University of Cambridge. The mice used in this study for obtaining the brains, livers and muscles were group-housed and maintained in cages with standard bedding and enrichment. Mice were maintained in a temperature and humidity-controlled room on a 12 h light cycle with ad libitum access to water and standard laboratory chow diet. Water and cages were autoclaved. The ratio of sexes of used mice was 1:1 (for 48 h fasting) or only females were used for 23 h fasting experiment. In general, n=4-6 mice were used per group and experiments were repeated at least twice. The number of the mice used for the experiments are indicated for each experiment in the figure legends. No other inclusion or exclusion criteria were used. No significant differences of AcCoA levels or acetylated Raptor levels between sexes were observed.

Method Details {#sec3.4}
--------------

### Antibodies and Reagents {#sec3.4.1}

The following antibodies have been used in this work: mouse anti-Flag M2 (\#F3165), rabbit anti-Actin (\#A2066) and mouse anti-α-Tubulin (\#T9026) from Sigma Aldrich; mouse anti-GAPDH clone 6C5 (\#ab8245) and rabbit anti-AUH (\#ab157453) from Abcam; rabbit anti-MCCC1 (\#NBP1-81254; Novus Biologicals); goat anti-Raptor (\#sc-27744) and rabbit anti-EP300 (\#sc-585) from SantaCruz Biotechnology; mouse anti-GFP (\#632375 and \#632592; Clontech); rabbit anti-phospho-Raptor (Ser863; \#12778; Signalway); mouse anti-HA.11 clone 16B12 (\#MMS-101P, Covance); mouse anti-EP300 (\#05-257) from Millipore; mouse anti-LAMP1 clone H4A3 (obtained from Developmental Studies Hybridoma Bank, University of Iowa); mouse anti-c-Myc clone 9E10 (\#11667203001; Roche); rabbit anti-LAMP1 (\#9091), rabbit anti-mTOR (\#2972), rabbit anti-phospho-mTOR (Ser2481; \#2974), rabbit anti-phospho-p70S6kinase (p-S6K1) (Thr389; \#9234), anti-total p70S6kinase (S6K1) (\#9202), rabbit anti-phospho-S6 Ribosomal Protein (p-S6) (Ser235/236; \#4856), rabbit anti-S6 Ribosomal Protein (S6) (\#2217), rabbit anti-phospho-4E-BP1 (Thr37/46; \#9459), rabbit anti-4E-BP1 (\#9452), rabbit anti-phospho-ULK1 (Ser757; \#6888), rabbit anti-ULK1 (\#4773), rabbit anti-phospho-Raptor (Ser792; \#2083), rabbit anti-Raptor (24C12) (\#2280), rabbit anti-acetylated-Lysine (Ac-K) (\#9814, \#9441), rabbit anti-Histone H3 (\#9715), rabbit anti-ATG7 (D12B11) (\#8558), rabbit anti-PRAS40 (D23C7) (\#2691), rabbit anti-mLST8 (86B8) (\#3274), rabbit anti-LAMTOR1/C11orf59 (\#8975), rabbit anti-RagA (D8B5) (\#4357), rabbit anti-RagB (\#8150) and rabbit anti-RagC (D8H5) (\#9480), anti-phospho-PKCα/β II (Thr638/641; \#9375), anti-PKCα (\#2056), anti-phospho-AKT (p-AKT) (Ser473;\#4060), anti-AKT (\#9272), anti-phospho-ATP-Citrate Lyase (p-ACLY)(Ser455; \#4331), anti-ATP-Citrate Lyase (ACLY) (\#4332) from Cell Signaling Technology; anti-mouse (\#NA931V) and anti-rabbit (\#NA934V) horseradish peroxidise (HRP)-conjugated secondary antibodies (GE Healthcare); anti-goat horseradish peroxidise (HRP)-conjugated secondary antibody (\#611620, Invitrogen/Life Technologies). All the primary antibodies were used at a dilution of 1:1,000 (overnight incubation at 4°C), unless otherwise stated, and the secondary antibodies used at a dilution between 1:2,000 and 1:4,000 (1 h of incubation at room temperature).

Drug treatments used include: DMSO, .1-10 μM leucine, .1-100 μM isoleucine, .1-100 μM valine, 1-10 μM KIC, 1 mM NAC, .1-1 mM DCA, 1-10 μM HCoA, .1-1 μM AcCoA, 10 μM c646, 10 μM Spermidine, 50 μM CTB, 20mM Potassium hydroxycitrate tribasic monohydrate (HC), 50 μM TSA from Sigma-Aldrich.

### Transfection {#sec3.4.2}

Trans IT-2020 reagent (Mirus) was used for DNA transfection, while Lipofectamine 2000 (Invitrogen) was used for siRNA transfections, according to the manufacturer's instructions. After transfection, cells were maintained in full medium. For knockdown experiments, unless otherwise specified in figure legends, cells were transfected with 50 nM siRNA followed by another 50 nM siRNA transfection after 48 h. Cells were split once in between both transfections and harvested after 3 days of transfection. The following DNA or siRNA/shRNA constructs were also used in this work: empty pEFGP and pcDNA3.1-myc-His (Invitrogen); pCMV6-XL5-MCCC1 (untagged) (\#SC113201) from Origene; pcDNA3.1-p300 (\#23252), pcDNA3.1-p300(HAT-) (\#23254), peYFP-C1-mTOR (\#73384), pRK5-HA-YFP-Raptor (\#73385), pRK5-HA-YFP-PRAS40 (\#73389), pRK5-HA-YFP-DEPTOR (\#73390), pRK5-HA-Raptor (\#8513), pRK5-HA-GST-RagB (\#19301), pLJM1-Flag-RagD (\#19316), pLJM1-Flag-Raptor-RHEB15 (\#26634) from Addgene. Pre-designed siRNAs (SMARTpool and/or set of deconvoluted oligos ON-TARGETplus4Non-targeting Control \#D-001810-10; RagA \#L-016070-00-0005, RagB \#L-012189-01-0005, LAMTOR1 \#L-020916-02-0005, AUH \#L-008457-00-0005, HMGCL \#L-019290-00-0005, KAT2A \#L-009722-02-0005, KAT2B \#L-005055-00-0005, KAT5 \#L-006301-00-0005, KAT8 \#L-014800-02-0005, EP300 \#L-003486-00-0005, Raptor \#L-004107-00-0005, Sestrin 1 \#L-020244-00-0005, Sestrin 2 \#L-019134-02-0005, LARS \#L-010171-00-0005, ACLY \#L-004915-00-0005) were obtained from Dharmacon-Thermo Scientific; For knockdown of MCCC1, we used siRNA from Ambion (\#AM51331, s32399, s32400, s32401) as well as from Dharmacon-Thermo Scientific (\#L-009429-00-0005). For knockdown of GLUD1, we used siRNA from Ambion (\#AM16708, 107673). Pre-designed pLKO.1 shRNAs vectors from The RNAi Consortium (TRC) (empty vector control \#RHS4080, Dharmacon; mouse Mccc1 \#RMM4534-EG72039). Although all the shRNAs provided by TRC were validated, we used to perform most of the experiments (TRCN0000112506 (\#B)).

### Western Blot Analysis {#sec3.4.3}

The tissue samples were lysed in tissue lysis buffer on ice (20 mM Tris-HCl (pH7.4), 5 mM EDTA, 150 mM NaCl, 0.5% Triton X-100, 10 mM sodium butyrate, 1 mM TSA and protease/phosphatase inhibitors cocktail) and the supernatant was centrifuged twice. Protein concentration was determined using the Bradford assay (Bio-Rad). Cells were lysed in Laemmli buffer and protein samples were boiled for 10 min at 100°C, separated by SDS-PAGE, transferred onto PVDF membranes, subjected to western blot analysis, finally visualized using an ECL enhanced chemiluminescence detection kit (GE Healthcare), or with direct infrared fluorescence detection on an Odyssey Infrared Imaging System. Densitometric analysis on the immunoblots was performed using ImageJ program or IMAGE STUDIO Lite software, which enables quantitative analysis of blotting signals.

### Starvation for Primary Cortical Neurons {#sec3.4.4}

For starvation experiments with primary neurons, neurons were washed twice in either maintenance media or artificial CSF (ACSF) (10 mM HEPES, pH 7.4, 125 mM NaCl, 5 mM KCl, 2 mM CaCl~2~, 1 mM MgCl~2~, 10 mM glucose) and incubated in maintenance media or ACSF for 4 h.

### shRNA Lentivirus Production and Infection {#sec3.4.5}

shRNA lentiviral particles were produced and transduced following The RNAi Consortium (TRC) protocols. Briefly, HEK-293T packaging cells growing in 100 mm dishes were transfected at 60--70% of confluence with a mix of 2.5 μg psPAX2 vector (packaging vector), 270 ng pMD2.G vector (envelope vector) and 2.7 μg hairpin-pLKO.1 vector. TransIT-LT1 (Mirus) was used as transfection reagent according to the manufacturer's instructions. After transfection, cells were cultured in high-serum medium (20% FBS). Cell culture medium was harvested three times for intervals of 24 h. Viral preps were then concentrated by centrifugation at 160,100g for 90 min. For primary neurons, 20 μl of viral preps were added to the cells in the presence of 4 μg/ml polybrene (Sigma Aldrich) and were incubated for 24 h. The medium was replaced by full medium and cells were further incubated for an additional 4 days before testing the knockdown effects.

### Food Deprivation in Mice {#sec3.4.6}

All animal studies were performed under the jurisdiction of appropriate Home Office Project and Personal animal licences and with local Ethics Committee approval from the University of Cambridge. For fasting, we used two different procedures. Either, the 6-weeks-old C57BL/6 male or female mice were deprived of food for 48 h with free access to water throughout the procedure, as described previously ([@bib1]). After 22.5 h starvation, mice were given free access to food for 1.5 h followed by a second round of starvation for another 22.5 h. Our rationale is that this procedure synchronises the starvation. Alternatively, mice were deprived of food for 23 h with free access to water throughout the procedure. The tissues were collected and frozen for immunoblot and immunoprecipitation analysis.

### Mutagenesis {#sec3.4.7}

Mutagenesis of the human Raptor was generated with QuikChange Site-Directed Mutagenesis Kit (Agilent Stratagene) according to manufacturer's instructions, using the set of primers:1)5'-ccaaatcagcaaaattcctccagaccctgatggca-3' (forward), 5'-tgccatcagggtctggaggaattttgctgatttgg-3' (reverse) to convert the residue Lys1097 into an Arg (K1097R)2)5'-cacggtggccctgtaggcgatgctgttgag-3' (forward), 5'-ctcaacagcatcgcctacagggccaccgtg-3' (reverse) to convert the residue Lys840 into an Arg (K840R)

DPN I digestion was performed after PCR and XL-10 gold-competent cells were transformed, and through sequencing, Raptor mutants from a positive clone were selected.

### Immunofluorescence {#sec3.4.8}

For immunofluorescence, the HeLa, HEK-293T or primary neurons were fixed for 5 min with ice cold methanol or for 10 min with 4% paraformaldehyde (PFA). Concentration of the primary and secondary antibodies are described below. The mounting solution was from Molecular Probes.

Dilution of primary antibodies. 1:300 rabbit anti-mTOR; 1:600 mouse anti-LAMP1; 1:300 anti-phospho-S6 Ribosomal Protein; 1:400 rabbit anti-acetylated-Lysine (Ac-K); 1:500 rabbit anti-RagC; 1:200 rabbit anti-EP300; 1:200 goat anti-Raptor; 1:600 goat anti-HA (\#NB600-362; Novus Biologicals); 1:1000 mouse anti-HA.11 clone 16B12.

The secondary antibodies Alexa 488, 555, 568, 594 or 647 goat anti-mouse, goat anti-rabbit or rabbit anti-goat were obtained from Molecular Probes and used at 1:400. Imaging was conducted with LSM780 Zeiss confocal with 63X oil-immersion lense. The colocalization was measured using Volocity software for Mander\'s Overlap Coefficient (MOC) or Pearson\'s correlation coefficient (PCC). These procedures were performed in a blinded fashion.

### Cytosolic/Nuclear Fractionation {#sec3.4.9}

Cells were washed twice with ice-cold PBS and lysed with Buffer A (10 mM HEPES, 10 mM KCl, 0.1 mM EDTA, 0.4% NP-40, 1 mM DTT and protease/phosphatase inhibitors cocktail) and incubated on ice for 20 min. After homogenization, the lysates were centrifuged at 16,100g at 4°C for 10 min. Supernatants containing cytosolic proteins were harvested and nuclear pellets were resuspended with Buffer B (20 mM HEPES, 0.4 M NaCl, 1 mM EDTA, 10 % glycerol, 1 mM DTT and protease/phosphatase inhibitors cocktail) and incubated for 1 h on ice. After centrifugation at 16,100g for 10 min at 4°C, the supernatants containing the nuclear proteins were collected. Protein concentration was determined using the Bradford assay (Bio-Rad). For AcCoA measurement, non-denatured total and cytosolic fractions were used, and for immunoblot, the fractions were denatured. Histone H3 or GAPDH were used as nuclear or cytosolic control.

### Acetyl-Coenzyme A (AcCoA) Measurement {#sec3.4.10}

The AcCoA content was determined on total or cytosolic fractions using the PicoProbe AcCoA assay kit (ab87546, Abcam) according to manufacturer's instructions. Briefly, after deproteinization using the perchloric acid, the CoASH Quencher and Quencher remover were added into the sample to correct the background generated by free CoASH and succ-CoA. The sample was then diluted with the reaction mix, and fluorescence was measured using a plate reader and the following settings: λex 535 nm; λem 587 nm. Fluorescence was measured using a Versamax Tunable microplate reader (Molecular Devices). The acetyl-CoA standard curve was made in the range of 0--100 pM and the correlation coefficient was 0.990 or higher.

### EP300 Activity Assay {#sec3.4.11}

The EP300 activty was determined using the SensoLyte EP300 assay kit (AS-72172, Anaspec) with some modification. Briefly, cell lysates or brain tissue lysates were incubated with AcCoA solution and substrates (H3) for 15 min at 37°C. Developer solution was added and incubated for 30 min at room temperature. The fluorescence was measured using a plate reader and the following settings: λex 389 nm; λem 513 nm. Fluorescence was measured using a Versamax Tunable microplate reader (Molecular Devices).

### Co-Immunoprecipitation (Co-IP) {#sec3.4.12}

Cells in 60 mm dishes were washed twice with PBS and lysed in ice-cold lysis buffer (40 mM HEPES (pH 7.4), 2 mM EDTA, 10 mM pyrophosphate, 10 mM glycerophosphate, and 0.3% CHAPS (for interaction of mTORC1 with Rag complex) or 0.5% Triton X-100 (for IP with Ac-K antibody) and protease/phosphatase inhibitors cocktail, and further supplemented with 10 mM sodium butyrate and 1 mM TSA for IP with Ac-K antibody. Lysates were incubated on ice for 20 min and isolated by centrifugation at 16,100g for 10 min. Supernatants were transferred to new tubes; 1/10 of the sample was kept as input control, while the remaining lysate was overnight incubated with primary antibodies at 4°C with gentle agitation. Thereafter, Dynabeads-protein G (Life Technologies) were added to the samples and incubated at 4°C for 2 h. Beads were washed three times with lysis buffer and the immunoprecipitated proteins were eluted and denatured with 2 X Laemmli buffer and boiled for 5 min. For co-transfection experiments, HeLa cells were transfected with the indicated plasmids as follows: 1000 ng or 500 ng myc-mTOR in pRK5 or peYFP-C1-mTOR; 500 ng HA-, YFP-Raptor with or without point mutation in pRK5; 100 ng HA-GST-RagB in pRK5; 100 ng HA-GST-RagD in pRK5 or Flag-RagD in pLJM1. The total amount of plasmid DNA in each transfection was normalized to 2 μg with empty pRK5. For analysis of acetylated Raptor in tissues, we used tissue lysis buffer (20 mM Tris-HCl (pH7.4), 5 mM EDTA, 150 mM NaCl, 0.5% Triton X-100, 10 mM sodium butyrate, 1 mM TSA and protease/phosphatase inhibitors cocktail) and 150 μg of lysates was used for IP.

### GFP-Trap for IP of GFP (or YFP)-Fusion Proteins {#sec3.4.13}

The IP of GFP or YFP-fusion proteins was performed using GFP-Trap (gtma-100, ChromoTek) according to manufacturer's instructions with some modification. Briefly, cells in 60 mm dishes were lysed in ice-cold lysis buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5 mM EDTA and 0.3% CHAPS and protease/phosphatase inhibitors cocktail). 0.5ml of cell lysate was incubated for 1 h at 4°C with 20 μl of GFP-Trap slurry, and then the beads were washed 2 times with the wash buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5 mM EDTA). 60 μl of 2X sample buffer were added, and boiled for 10 min at 100°C, separated by SDS-PAGE.

### Mitochondrial Morphology Analysis {#sec3.4.14}

Mitochondrial morphology was investigated using MitoTracker green FM (M7514, Invitrogen) according to manufacturer's instructions. Briefly, control or MCCC1 siRNA transfected cells for 48 h were stained with 100 nM MitoTracker Green FM for 20 min to visualize mitochondrial morphology and then washed 2 times with Opti-MEM. Images were captured with LSM880 Zeiss confocal with 63X oil-immersion lens and quantified using the ImageJ program. These procedures were performed in a blinded fashion.

### Assessment of Oxidative Stress {#sec3.4.15}

For analyzing the oxidative stress on control or MCCC1 knockdown cells, cells were incubated in 2 μM of MitoSOX Red reagent (Molecular Probes), which is a specific superoxide marker in mitochondria, and 500 nM of Mitotracker Green FM (Molecular Probes) for 10 min at 37°C. Fluorescent intensity and distribution were observed using LSM880 Zeiss confocal with 63X oil-immersion lense. The intensity was measured using Volocity software.

Quantification and Statistical Analysis {#sec3.5}
---------------------------------------

### Image Analysis {#sec3.5.1}

Volocity software (PerkinElmer) was used for analysis and processing of confocal images. For co-localization analysis of confocal images, we used Mander\'s Overlap Coefficient (MOC) or Pearson\'s Correlation Coefficient (PCC). A minimum of 30 cells were examined for each condition. All experiments were repeated at least three times. The background was fixed for all within-experiment analyses. See details in the figure legends.

### Statistical Analysis {#sec3.5.2}

Significance levels for comparisons between groups were determined with unpaired or paired two-tailed Student's t-test using GraphPad Prism 5 (GraphPad Software) or Excel (Microsoft Office), where appropriate. For western blots, protein levels were normalized to total forms or a housekeeping protein, such as tubulin or GAPDH. All data were expressed as means ± standard error of the mean (S.E.M). P values of \< 0.05 were considered statistically significant. Sample sizes were chosen on the basis of extensive experience with the assays we have performed. The experiments were appropriately randomized. We have not formally tested whether the data met the assumptions of the statistical approach, but these assays and data are typically analysed in the literature with the approaches we have used. The statistical parameters are specified within the figure legends.

Data and Software Availability {#sec3.6}
------------------------------

The authors declare that the data supporting the findings of this study are available within the article and its [Supplemental Information](#app2){ref-type="sec"} files.
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